Cargando…
A Mass Spectrometry Imaging Based Approach for Prognosis Prediction in UICC Stage I/II Colon Cancer
SIMPLE SUMMARY: Tumor treatment is heavily dictated by the tumor progression status. However, in colon cancer, it is difficult to predict disease progression in the early stages. In this study, we have employed a proteomic analysis using matrix-assisted laser desorption/ionization mass spectrometry...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582467/ https://www.ncbi.nlm.nih.gov/pubmed/34771536 http://dx.doi.org/10.3390/cancers13215371 |
_version_ | 1784596993004273664 |
---|---|
author | Martin, Benedikt Gonçalves, Juliana P. L. Bollwein, Christine Sommer, Florian Schenkirsch, Gerhard Jacob, Anne Seibert, Armin Weichert, Wilko Märkl, Bruno Schwamborn, Kristina |
author_facet | Martin, Benedikt Gonçalves, Juliana P. L. Bollwein, Christine Sommer, Florian Schenkirsch, Gerhard Jacob, Anne Seibert, Armin Weichert, Wilko Märkl, Bruno Schwamborn, Kristina |
author_sort | Martin, Benedikt |
collection | PubMed |
description | SIMPLE SUMMARY: Tumor treatment is heavily dictated by the tumor progression status. However, in colon cancer, it is difficult to predict disease progression in the early stages. In this study, we have employed a proteomic analysis using matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI). MALDI-MSI is a technique that measures the molecular content of (tumor) tissue. We analyzed tumor samples of 276 patients. If the patients developed distant metastasis, they were considered to have a more aggressive tumor type than the patients that did not. In this comparative study, we have developed bioinformatics methods that can predict the tendency of tumor progression and advance a couple of molecules that could be used as prognostic markers of colon cancer. The prediction of tumor progression can help to choose a more adequate treatment for each individual patient. ABSTRACT: Currently, pathological evaluation of stage I/II colon cancer, following the Union Internationale Contre Le Cancer (UICC) guidelines, is insufficient to identify patients that would benefit from adjuvant treatment. In our study, we analyzed tissue samples from 276 patients with colon cancer utilizing mass spectrometry imaging. Two distinct approaches are herein presented for data processing and analysis. In one approach, four different machine learning algorithms were applied to predict the tendency to develop metastasis, which yielded accuracies over 90% for three of the models. In the other approach, 1007 m/z features were evaluated with regards to their prognostic capabilities, yielding two m/z features as promising prognostic markers. One feature was identified as a fragment from collagen (collagen 3A1), hinting that a higher collagen content within the tumor is associated with poorer outcomes. Identification of proteins that reflect changes in the tumor and its microenvironment could give a very much-needed prediction of a patient’s prognosis, and subsequently assist in the choice of a more adequate treatment. |
format | Online Article Text |
id | pubmed-8582467 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85824672021-11-12 A Mass Spectrometry Imaging Based Approach for Prognosis Prediction in UICC Stage I/II Colon Cancer Martin, Benedikt Gonçalves, Juliana P. L. Bollwein, Christine Sommer, Florian Schenkirsch, Gerhard Jacob, Anne Seibert, Armin Weichert, Wilko Märkl, Bruno Schwamborn, Kristina Cancers (Basel) Article SIMPLE SUMMARY: Tumor treatment is heavily dictated by the tumor progression status. However, in colon cancer, it is difficult to predict disease progression in the early stages. In this study, we have employed a proteomic analysis using matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI). MALDI-MSI is a technique that measures the molecular content of (tumor) tissue. We analyzed tumor samples of 276 patients. If the patients developed distant metastasis, they were considered to have a more aggressive tumor type than the patients that did not. In this comparative study, we have developed bioinformatics methods that can predict the tendency of tumor progression and advance a couple of molecules that could be used as prognostic markers of colon cancer. The prediction of tumor progression can help to choose a more adequate treatment for each individual patient. ABSTRACT: Currently, pathological evaluation of stage I/II colon cancer, following the Union Internationale Contre Le Cancer (UICC) guidelines, is insufficient to identify patients that would benefit from adjuvant treatment. In our study, we analyzed tissue samples from 276 patients with colon cancer utilizing mass spectrometry imaging. Two distinct approaches are herein presented for data processing and analysis. In one approach, four different machine learning algorithms were applied to predict the tendency to develop metastasis, which yielded accuracies over 90% for three of the models. In the other approach, 1007 m/z features were evaluated with regards to their prognostic capabilities, yielding two m/z features as promising prognostic markers. One feature was identified as a fragment from collagen (collagen 3A1), hinting that a higher collagen content within the tumor is associated with poorer outcomes. Identification of proteins that reflect changes in the tumor and its microenvironment could give a very much-needed prediction of a patient’s prognosis, and subsequently assist in the choice of a more adequate treatment. MDPI 2021-10-26 /pmc/articles/PMC8582467/ /pubmed/34771536 http://dx.doi.org/10.3390/cancers13215371 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Martin, Benedikt Gonçalves, Juliana P. L. Bollwein, Christine Sommer, Florian Schenkirsch, Gerhard Jacob, Anne Seibert, Armin Weichert, Wilko Märkl, Bruno Schwamborn, Kristina A Mass Spectrometry Imaging Based Approach for Prognosis Prediction in UICC Stage I/II Colon Cancer |
title | A Mass Spectrometry Imaging Based Approach for Prognosis Prediction in UICC Stage I/II Colon Cancer |
title_full | A Mass Spectrometry Imaging Based Approach for Prognosis Prediction in UICC Stage I/II Colon Cancer |
title_fullStr | A Mass Spectrometry Imaging Based Approach for Prognosis Prediction in UICC Stage I/II Colon Cancer |
title_full_unstemmed | A Mass Spectrometry Imaging Based Approach for Prognosis Prediction in UICC Stage I/II Colon Cancer |
title_short | A Mass Spectrometry Imaging Based Approach for Prognosis Prediction in UICC Stage I/II Colon Cancer |
title_sort | mass spectrometry imaging based approach for prognosis prediction in uicc stage i/ii colon cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582467/ https://www.ncbi.nlm.nih.gov/pubmed/34771536 http://dx.doi.org/10.3390/cancers13215371 |
work_keys_str_mv | AT martinbenedikt amassspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer AT goncalvesjulianapl amassspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer AT bollweinchristine amassspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer AT sommerflorian amassspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer AT schenkirschgerhard amassspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer AT jacobanne amassspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer AT seibertarmin amassspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer AT weichertwilko amassspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer AT marklbruno amassspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer AT schwambornkristina amassspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer AT martinbenedikt massspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer AT goncalvesjulianapl massspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer AT bollweinchristine massspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer AT sommerflorian massspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer AT schenkirschgerhard massspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer AT jacobanne massspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer AT seibertarmin massspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer AT weichertwilko massspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer AT marklbruno massspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer AT schwambornkristina massspectrometryimagingbasedapproachforprognosispredictioninuiccstageiiicoloncancer |